Together with JEMPERLI logo

Together with JEMPERLI is more than a program—it’s our promise to understand your needs, listen to what matters most to you, and create meaningful connections along the way.

Once your doctor has prescribed JEMPERLI, we will help you to understand the medication coverage process, investigate affordable options, and guide you through your care.

Here’s what you can expect from Together with JEMPERLI:

.

Coverage Support
We’ll check your insurance coverage and help you understand your benefits.* Together with JEMPERLI is here to help you navigate coverage and provide ongoing support.

  *The information provided by Together with JEMPERLI is not a guarantee of coverage or payment.

.

Cost Support
We’re here to let you know about the options for help paying for JEMPERLI if you are eligible.

.

Patient Support
Your Patient Navigator is at the heart of our program, offering tailored support throughout your treatment journey.

  †The Patient Navigator does not provide medical advice and is not a part of your doctor’s care team. Please ask your doctor any questions that you might have about your disease and treatment with JEMPERLI.

.

Discover More

Explore additional benefits of Together with JEMPERLI and enroll.

Learn More Enroll Now

Once you are enrolled, your support will be tailored to you

.

You Have Cost Support Options
Paying for medicine is not one-size-fits-all. The necessary support can be vastly different depending on your needs and insurance coverage. Together with JEMPERLI offers assistance with finding affordable options like copay or patient assistance programs for eligible patients.
Learn more

.

JEMPERLI Copay Program
Eligible, commercially insured patients may pay as little as $0 for JEMPERLI.

The JEMPERLI Copay Program helps eligible commercially insured patients with their eligible out-of-pocket costs for JEMPERLI.

  ‡Program annual maximums apply.
Visit TogetherwithJEMPERLI.com for information about eligibility and full program terms and conditions.

.

You Have a Patient Navigator§ in Your Corner
Your Patient Navigator can answer questions about insurance benefits and out-of-pocket costs. They can help you understand financial assistance and provide you with information about the product.

  §The Patient Navigator does not provide medical advice and is not a part of your doctor’s care team. Please ask your doctor any questions that you might have about your disease and treatment with JEMPERLI.

Downloadable resources

.

JEMPERLI Patient Brochure

Learn more about JEMPERLI in this informative brochure, ready to download or print.

Download PDF

.

Knowledge Is Gold Brochure

An in-depth look into terms and concepts behind endometrial cancer and a JEMPERLI clinical trial.

.

Celebrate the JEMs Brochure

A care partner's guide to supporting your loved one through milestones, or JEMs, they may experience throughout their treatment journey.

.

Discussion Guide

Learn how to start conversations about endometrial cancer and your JEMPERLI treatment with your care team, loved ones, and community.

Download PDF

.

Wellness Guide

Here you’ll find information about endometrial cancer, learn what you may expect during treatment, and get tips for talking to your care team about general wellness.

Download PDF

.

Side Effects Guide

Learn more about potential side effects associated with JEMPERLI treatment.

Download PDF

.

Care Partner Guide

Created especially for care partners, this guide explains how to support a loved one throughout their endometrial cancer journey. It also includes tips on taking care of themselves.

Download PDF

.

Glossary

To provide you with a better understanding of the terms, acronyms, and phrases that may be frequently used by your care team.

Download PDF

Frequently asked questions

  • What is JEMPERLI?

    JEMPERLI is a prescription medicine used to treat adults with:

    • a kind of uterine cancer called endometrial cancer (EC)
      • JEMPERLI may be used in combination with the chemotherapy medicines, carboplatin and paclitaxel, and then after that JEMPERLI may be used alone:
        • when your cancer has spread outside your uterus (advanced) or,
        • your cancer has returned.
      • JEMPERLI may be used alone:
        • when a laboratory test shows that your tumor is mismatch repair deficient (dMMR), and
        • your cancer has returned, or it has spread (advanced EC), and
        • you have received chemotherapy that contains platinum and it did not work or is no longer working, and
        • your cancer cannot be treated by surgery or radiation.
    • a kind of cancer that is shown by laboratory test to be dMMR solid tumor. JEMPERLI may be used alone to treat:
      • cancer that has returned or has spread (advanced cancer) and,
      • has progressed during treatment or after treatment, and you have no satisfactory treatment options.
      • This use is approved based on how many patients responded to treatment and how long they responded. Studies are ongoing to confirm the clinical benefit of JEMPERLI for this use.

    It is not known if JEMPERLI is safe and effective in children.

  • How is JEMPERLI given?

    JEMPERLI is given through an intravenous (IV) infusion. It takes approximately 30 minutes.

  • What is immunotherapy?

    Immunotherapy (IH-myoo-noh-THAYR-uh-pee) is a treatment that is designed to work with the body’s immune system to attack cancer cells. JEMPERLI is an immunotherapy that may help your body’s immune system fight cancer.

  • What does dMMR mean?

    dMMR stands for “mismatch repair deficient.” It describes cancers that have an MMR system that is not working properly to correct errors in the genes. dMMR is an important biomarker in endometrial cancer.

  • What is a biomarker?

    A biomarker (BY-oh-MAR-ker) is a molecule found in the tissues or fluids of your body that shows if a condition, process, or disease is normal or abnormal. Endometrial cancer may have a biomarker known as dMMR (mismatch repair deficient). Testing for this biomarker provides important information about your cancer and may help your doctor decide what treatment options, including JEMPERLI, may be right for you.

  • Why is it important to test for biomarkers?

    Testing for biomarkers like dMMR provides information about your cancer and may help your doctor decide what treatment options, including JEMPERLI, may be appropriate for you.

  • How common is endometrial cancer?

    Endometrial cancer is the most common gynecologic malignancy in the US. In 2025, an estimated 62,000 cases will be diagnosed in the US.

  • Is advanced or returned endometrial cancer common?

    About 1 in 4 people with endometrial cancer has cancer that has spread outside the uterus (advanced) or has returned.

  • How many people with endometrial cancer have the dMMR biomarker?

    dMMR is a fairly common biomarker—up to 30% of people with endometrial cancer have it.

  • How has JEMPERLI been studied?

    Researchers have conducted clinical trials to study the effectiveness, risks, and side effects associated with JEMPERLI. Trials are ongoing.

  • How many people participated in the clinical trial of JEMPERLI in combination with carboplatin and paclitaxel?

    There were 494 patients included in the clinical trial that studied the effectiveness of JEMPERLI in combination with the chemotherapy medicines, carboplatin and paclitaxel, compared to carboplatin and paclitaxel alone. They had endometrial cancer that was newly-diagnosed and had spread outside the uterus (advanced) or had returned.

    The clinical trial also studied the risks and side effects of JEMPERLI in combination with the chemotherapy medicines, carboplatin and paclitaxel, in 241 people with newly-diagnosed advanced or returned endometrial cancer.

  • How many people participated in the clinical trial of JEMPERLI alone for advanced or returned dMMR endometrial cancer?

    The clinical trial that studied the effectiveness of JEMPERLI alone included 141 people. They had dMMR endometrial cancer that had returned or spread (advanced); they had also previously received chemotherapy containing platinum that did not work or stopped working.

    The clinical trial also studied the risks and side effects of JEMPERLI alone in 150 people who had advanced or returned dMMR endometrial cancer.

  • How many people participated in the clinical trial of JEMPERLI alone for advanced or returned dMMR solid tumors?

    The clinical trial that studied the effectiveness of JEMPERLI alone for dMMR solid tumors included 209 people. They had dMMR solid tumors that had returned or spread (advanced cancer) and had progressed during or after treatment and had no satisfactory treatment options.

    The clinical trial also studied the risks and side effects of JEMPERLI alone in 267 people who had advanced or returned dMMR solid tumors.

    Studies are ongoing to confirm the clinical benefit of JEMPERLI for this use.

  • What types of dMMR solid tumors were studied in the clinical trial of JEMPERLI alone?

    These people had a variety of dMMR tumor types, including:

    • Endometrial cancer
    • Colorectal cancer
    • Small intestinal cancer
    • Gastric cancers
    • Pancreatic carcinoma
    • Biliary neoplasm
    • Liver cancer
    • Ovarian cancer
    • Adrenal cortical
    • Breast cancer
    • Esophageal cancer
    • Malignant neoplasm of the female genitals
    • Pleural
    • Renal cell carcinoma
    • Unknown origin

    If you have a dMMR solid tumor, talk to your doctor about treatment options.

  • Does GSK offer support and access to resources for people being treated with JEMPERLI?

    Yes. Together with JEMPERLI is a patient support program available once your doctor has prescribed JEMPERLI. Once enrolled, Together with JEMPERLI will help you to understand the medication coverage process, investigate affordable options, and guide you through your care. Learn more at TogetherwithJEMPERLI.com.

    The information provided by Together with JEMPERLI is not a guarantee of coverage.

.

Wellness Guide

Here you’ll find information about endometrial cancer, learn what you may expect during treatment, and get tips for talking to your care team about general wellness.

Download PDF

.

Glossary 

To provide you with a better understanding of the terms, acronyms, and phrases that may be frequently used by your care team.

Download PDF

.

Care Partner Guide

Created especially for care partners, this guide explains how to support a loved one throughout their endometrial cancer journey. It also includes tips on taking care of themselves.

Download PDF

.

Side Effects Guide

Learn more about potential side effects associated with JEMPERLI treatment.

Download PDF

.

Discussion Guide

Learn how to start conversations about endometrial cancer and your JEMPERLI treatment with your care team, loved ones, and community.

Download PDF